Ifebemtinib and paclitaxel synergistically inhibit the proliferation and metastasis of TNBC by blocking PI3K/Akt pathway through LSD1/PIK3IP1 axis
Yong Li, Lianfang Li, Qixin Mao, Shanqing Liu, Yan Shen, Wanying Zhao, Shaohua Zheng, Sai-Qi Wang, Xiao-Bing Chen · 2025
Read Ifebemtinib and paclitaxel synergistically inhibit the proliferation and metastasis of TNBC by blocking PI3K/Akt pathway through LSD1/PIK3IP1 axis by Yong Li, Lianfang Li, Qixin Mao, Shanqing Liu, Yan Shen, Wanying Zhao, Shaohua Zheng, Sai-Qi Wang, Xiao-Bing Chen (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12663599.txt.
Description
Yong Li and co-authors tested a two-drug pairing against triple-negative breast cancer in a 2025 study. This cancer type lacks the usual hormone targets and stays hard to treat. The pairing joins ifebemtinib, a FAK blocker, with the chemo drug paclitaxel. FAK runs high in these tumors and tracks with poor outlook.
In lab cultures, the pair curbed growth and colony forming more than either drug alone. It froze the cell cycle and tipped cells into death. Spread signals fell as cell glue proteins rose. A gene axis named in the paper carries the blocking effect. The work sets up animal and clinical follow-ups.
Catalog record
| CREATOR | Yong Li, Lianfang Li, Qixin Mao, Shanqing Liu, Yan Shen, Wanying Zhao, Shaohua Zheng, Sai-Qi Wang, Xiao-Bing Chen |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 60 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |